These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18762671)

  • 1. Abciximab in coronary intervention for acute myocardial infarction and stable ischemic heart disease: early investment for growing benefit.
    Ferenczi EA; Malik IS; Mayet J; Foale RA; Francis DP
    J Invasive Cardiol; 2008 Sep; 20(9):437-41. PubMed ID: 18762671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
    Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
    Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
    Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
    Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
    Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on mortality of abciximab in ST-elevation myocardial infarction treated with percutaneous coronary intervention including stent implantation.
    Tornvall P; Nilsson T; Lagerqvist B
    J Intern Med; 2006 Oct; 260(4):363-8. PubMed ID: 16961673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.
    Navarese EP; Kozinski M; Obonska K; Margheri M; Gurbel PA; Kubica J; De Luca G
    Platelets; 2012; 23(4):274-81. PubMed ID: 21988317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up.
    Mukherjee D; Topol EJ; Bertrand ME; Kristensen SD; Herrmann HC; Neumann FJ; Yakubov SJ; Bassand JP; McClure RR; Stone GW; Ardissino D; Moliterno DJ;
    Eur Heart J; 2005 Dec; 26(23):2524-8. PubMed ID: 16107485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T; Sederholm-Lawesson S; Stenestrand U; Alfredsson J; Janzon M; Swahn E
    Acute Card Care; 2010 Mar; 12(1):10-7. PubMed ID: 20201657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
    Huang R; Sacks J; Thai H; Goldman S; Morrison DA; Barbiere C; Ohm J
    Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of abciximab (c7E3 Fab, ReoPro) as an adjunct to balloon angioplasty.
    McGregor M; Brophy JM
    Can J Cardiol; 1999 Feb; 15(2):201-7. PubMed ID: 10079780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
    Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
    Bakhai A; Stone GW; Grines CL; Murphy SA; Githiora L; Berezin RH; Cox DA; Stuckey T; Griffin JJ; Tcheng JE; Cohen DJ;
    Circulation; 2003 Dec; 108(23):2857-63. PubMed ID: 14610016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.
    Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R
    J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO; Veloso HH; Braga De Paiva JM; Filho MW; Vincenzo De Paola AA
    Am Heart J; 2004 Dec; 148(6):937-43. PubMed ID: 15632875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economics of adjunctive therapies in coronary angioplasty: drugs, devices, or both?
    Oh PI; Cohen EA; Mittmann N; Seung SJ
    Can J Clin Pharmacol; 2004; 11(2):e202-11. PubMed ID: 15520474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty.
    Fuchs S; Kornowski R; Mehran R; Gruberg L; Satler LF; Pichard AD; Kent KM; Stone GW; Leon MB
    J Invasive Cardiol; 2000 Oct; 12(10):497-501. PubMed ID: 11022207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.